Hydroquinone percentages need a complete product name

The current Spot On offer advertises hydroquinone 6% and kojic acid 6%, with niacinamide also named. Its product page describes a compounded cream. These are provider-published specifications; this publication has not examined a prescription or a supplied container. The public material does not establish the niacinamide concentration, complete base or physical amount dispensed. Current Spot On records and the product description support those limited observations.

Keeping those gaps beside the numbers prevents a partly described formula from becoming an apparently complete one. The CoreAge document review examines the offer in more detail. An ingredient list in promotional copy is still a different record from the exact preparation a clinician might prescribe.

The inspected TRI-LUMA label names fluocinolone acetonide 0.01%, hydroquinone 4% and tretinoin 0.05%. It describes one topical combination cream. Removing the corticosteroid and retinoid from that description leaves an inaccurate picture of the labeled medicine. Its hydroquinone percentage is not a stand-alone comparison arm for every other hydroquinone preparation. TRI-LUMA prescribing information ties the ingredients to that finished product.

The indication is also specific: short-term treatment of moderate to severe facial melasma with sun-avoidance measures, including sunscreen. It is not a general approval for every dark spot or for indefinite maintenance. None of these product-specific details establishes that Spot On has the same evidence, or that an advertised alternative should inherit the label's results.

To claim that one preparation produces a better outcome, a source would need more than two concentration statements. Relevant evidence would identify the actual products, people studied, condition, comparison and outcome assessed. The provider-record comparison therefore treats published formulas as descriptions rather than positions on an effectiveness scale.

The TRI-LUMA label itself records limits: its safety and efficacy were not studied for hyperpigmentation conditions other than facial melasma, or in people with Fitzpatrick skin types V and VI. Those omissions do not predict an individual's response. They do show why even a detailed approved label cannot answer every question about every reader or preparation. A numerical ranking would erase that important context.

The American Academy of Dermatology explains that a dermatologist can distinguish melasma from another condition and may use a closer examination or, sometimes, a biopsy. A sales category such as dark spots cannot do that work. Its melasma guidance describes individualized goals and assessment rather than a universally best treatment.

A person can accurately describe when a change appeared without assigning it a medical name. The dark-spot assessment guide develops that distinction. A concentration comparison made before the clinical question is understood can sound precise while addressing the wrong problem. Even descriptions that share words such as pigmentation or uneven tone may cover different causes, locations and histories.

Spot On's additional kojic acid and niacinamide do not establish that the finished mixture prevents irritation or offsets every hydroquinone risk. TRI-LUMA has its own warnings, including possible exogenous ochronosis, described as gradual blue-black darkening. That is a warning in the exact label, not a sign that treatment is succeeding. A new concerning change needs professional attention rather than interpretation through an advertising promise. Label warnings remain relevant evidence with a product-specific scope.

Questions about other products, prior reactions and the complete base belong with the prescriber and pharmacist. Reading an ingredient's proposed purpose is not the same as assessing the combination for a person. No percentage in this article supplies that assessment.

Useful questions are concrete: What is the full prescribed formula? Which preparation's evidence is being discussed? What does the supplied label identify, and whom should the patient contact about an unexpected change? The preparation-context reader keeps the public statement, its limit and the professional question together.

FDA distinguishes compounded preparations from FDA-approved generics; the categories are not interchangeable. Its compounding explanation also notes that people obtaining compounded drugs online may not know who compounded them. The compounding-status guide explains why an ingredient name and prescription requirement do not fill that gap. A professional's explanation should refer to the proposed product, not merely repeat an attractive percentage.

Pigment in Practice is prepared for the CoreAge Rx promotional network, and CoreAge receives first commercial placement. Readers should weigh that relationship when using the provider pages. It does not turn a listed concentration into proof of clinical superiority, and this article is not a report of patient testing or a clinician's assessment of an individual.

The most useful end point for this reading exercise is a better-defined question. It may be about the preparation, the condition being considered, the relevance of a particular study or a missing dispensing detail. None of those questions is resolved simply by choosing the largest percentage on the page.